论文部分内容阅读
目的:探讨主要组织相容性复合体(MHCIb,HLA-DR)、血管内皮生长因子(VEGF)、共刺激分子(hB7-1)在人卵巢上皮性肿瘤组织中的表达与卵巢上皮性肿瘤发生、发展、预后及肿瘤免疫逃逸的关系,为卵巢癌的生物、基因治疗以及预后的评价提供理论依据。方法:选择1999-01/2003-12本院手术切除的人卵巢上皮癌存档标本52块。选择交界性卵巢上皮肿瘤10块,良性卵巢肿瘤10块,正常卵巢组织10块作为对照。采用SP免疫组化技术检测MHCIb,HLA-DR,hB7-1,VEGF在卵巢上皮性肿瘤中的表达。结果:MHCIb,HLA-DR在卵巢上皮癌中的表达分别为14%,59%,与正常卵巢组织及良性肿瘤比较差异均具有显著性意义(P<0.01或P<0.05),其中HLA-DR表达与组织学类型、临床分期有关,低分化腺癌和宫内膜样癌以及I～II期和III～IV期的表达强度相比差异均有明显意义(P<0.01或P<0.05);VEGF抗原在52例卵巢上皮癌的表达阳性率为75%,与正常卵巢组织及良性肿瘤比较差异有显著性意义(P<0.01),且与临床分期有关,I～II期和III～IV期的表达强度相比差异有明显意义(P<0.01);hB7-1抗原在52例卵巢上皮癌的表达阳性率为20%,较正常卵巢组织及良性肿瘤差异均具有显著性意义(P<0.01或P<0.05)。结论:,卵巢上皮癌组织中MHCIb,HLA-DR,hB7-1,VEGF表达的变化在机体自身抗卵巢肿瘤免
Objective: To investigate the expression of major histocompatibility complex (MHC Bb, HLA-DR), vascular endothelial growth factor (VEGF) and costimulatory molecule (hB7-1) in epithelial ovarian tumor and ovarian epithelial neoplasia , Development, prognosis and tumor immune escape, providing theoretical basis for the biological, gene therapy and prognosis evaluation of ovarian cancer. Methods: Fifty-two specimens of human ovarian epithelial carcinoma surgically excised from January 1999 to December 2003 were selected. Select borderline ovarian epithelial tumor 10, benign ovarian tumor 10, normal ovarian tissue 10 as a control. The expression of MHC class I, HLA-DR, hB7-1 and VEGF in epithelial ovarian tumors was detected by SP immunohistochemistry. Results: The expressions of MHCb and HLA-DR in epithelial ovarian cancer were 14% and 59%, respectively, which were significantly different from those in normal ovarian tissues and benign tumors (P <0.01 or P <0.05) There were significant differences in the expression between histological type and clinical stage, between poorly differentiated adenocarcinoma and endometrioid carcinoma, as well as between I to II and III to IV (P <0.01 or P <0.05). The positive rate of VEGF antigen expression in 52 cases of epithelial ovarian cancer was 75%, which was significantly different from that in normal ovarian tissue and benign tumor (P <0.01), and was related to clinical stage. Stage I to II and stage III to IV (P <0.01). The positive rate of hB7-1 antigen in 52 cases of epithelial ovarian cancer was 20%, which was significantly higher than that in normal ovarian tissue and benign tumor (P <0.01) Or P <0.05). Conclusion: The expression of MHC Ib, HLA-DR, hB7-1 and VEGF in epithelial ovarian cancer tissues varies with the changes of their own anti-ovarian tumor